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HEMATOPOIESIS
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast
expansion during the erythropoietic stress response in vivo
Ying Liu, Ramona Pop, Cameron Sadegh, Carlo Brugnara, Volker H. Haase, and Merav Socolovsky
Erythropoietin (Epo) is the principal regu-
lator of the erythropoietic response to
hypoxic stress, through its receptor,
EpoR. The EpoR signals mediating the
stress response are largely unknown, and
the spectrum of progenitors that are
stress responsive is not fully defined.
Here, we used flow cytometry to identify
stress-responsive Ter119CD71highFSChigh
early erythroblast subsets in vivo. In the
mouse spleen, an erythropoietic reserve
organ, early erythroblasts were present at
lower frequencies and were undergoing
higher rates of apoptosis than equivalent
cells in bone marrow. A high proportion
of splenic early erythroblasts coex-
pressed the death receptor Fas, and its
ligand, FasL. Fas-positive early erythro-
blasts were significantly more likely to
coexpress annexin V than equivalent, Fas-
negative cells, suggesting that Fas medi-
ates early erythroblast apoptosis in vivo.
We examined several mouse models of
erythropoietic stress, including erythrocy-
tosis and -thalassemia. We found a dra-
matic increase in the frequency of splenic
early erythroblasts that correlated with
down-regulation of Fas and FasL from
their cell surface. Further, a single injec-
tion of Epo specifically suppressed early
erythroblast Fas and FasL mRNA and
cell-surface expression. Therefore, Fas
and FasL are negative regulators of eryth-
ropoiesis. Epo-mediated suppression of
erythroblast Fas and FasL is a novel
stress response pathway that facilitates
erythroblast expansion in vivo. (Blood.
2006;108:123-133)
© 2006 by The American Society of Hematology
Introduction
Multiple clinical and physiologic conditions give rise to tissue
hypoxia, resulting in up to a 10-fold increase in red-cell produc-
tion.1 Erythropoietin (Epo), whose receptor is expressed by ery-
throid progenitors, is the principal regulator of the erythropoietic
stress (hereafter referred to simply as ‘stress’) response.2 Epo
receptor (EpoR) is a homodimeric type I membrane protein of the
cytokine receptor superfamily,3-5 closely associated with the cyto-
plasmic tyrosine kinase Jak2.6-8 EpoR and Jak2 are each essential
for red-cell formation.9-13 Following EpoR ligation, the ensuing
Jak2 activation recruits multiple downstream signals including
Stat5, PI3 kinase, PLC, PKC, Grb2, Shc, and Ras.6,7
The requirement for EpoR signaling may be more stringent during
stress than during basal erythropoiesis. Mice expressing reduced num-
bers of EpoR,14 or an EpoR lacking cytoplasmic tyrosines,15 have
normal basal erythropoiesis, but a deficient stress response. Further,
mice lacking Stat5 are also deficient in their stress response and suffer
anemia and perinatal death.16-18 Therefore, EpoR signals during stress
differ quantitatively or qualitatively from the signals required for the
formation of red cells per se or for basal erythropoiesis. The intracellular
targets of EpoR during stress are largely unknown, and the spectrum of
erythroid progenitors in which they act is not fully defined. The recent
identification of an activating Jak2 mutation in myeloprolifera-
tive disorders19-22 emphasizes the importance of identifying physiologic
targets of high levels of Jak2 activation, as seen during erythropoietic
stress.
The study of erythroid progenitors during stress had been limited by
the lack of cell-surface markers with which to identify them in vivo.
Previous studies found that the number of erythroid colony-forming
units (CFU-Es) in spleen increases dramatically as a result of stress.23-26
EpoR is required for CFU-E survival in vitro,27 suggesting a similar
function during CFU-E expansion in vivo during stress.24,25,27 However,
to date there are no direct data to support this hypothesis.
The early erythroblast progeny of CFU-Es express the EpoR
and are potential Epo targets during stress.28-30 Recently, we
developed a flow cytometric assay that allows identification of
differentiation stage-specific erythroblasts directly in freshly iso-
lated hematopoietic tissue.17 We found that early erythroblasts are a
target of EpoR-mediated, Stat5-dependent antiapoptotic signaling,
through the immediate-early induction of the antiapoptotic protein
bcl-xL.16 The deficient stress response of Stat5-deficient mice was
associated with decreased expression of bcl-xL and decreased
survival of their early erythroblasts. These findings therefore
suggest the hypothesis that apoptotic regulators in early erythro-
blasts participate in the stress response.
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Here we investigate the role of Fas in erythroblast homeostasis.
Fas and its ligand (FasL) are integral membrane proteins of the
tumor necrosis factor (TNF) receptor and TNF superfamilies,
respectively.31,32 Clustering of cell-surface Fas by FasL triggers an
intracellular caspase cascade and cell death.32,33 Fas and FasL have
been detected on cultured erythroblasts, but reports are conflicting
regarding the level and differentiation stage at which they are
expressed.34-36 Fas has been implicated in erythroblast apoptosis in
myelodysplastic syndrome,37-40 multiple myeloma,41,42 -thalasse-
mia, 43 and following stimulation with interferon-,34 underscoring
the need to understand its role in erythropoiesis.
Fas and FasL have well-defined functions in immune cells, but
have been suggested to also play roles in nonimmune tissue.44-49
Mice mutant for Fas (lpr) or FasL (gld) develop a lymphoprolifera-
tive autoimmune syndrome.50 Of note, lpr mice have increased
numbers of multilineage myeloid progenitors (spleen colony-
forming units [CFU-Ss]), suggesting that Fas negatively regulates
these cells.51
Here we investigate Fas function in erythroblast homeostasis in
vivo in the mouse, in the basal state and during stress. Our findings
suggest that Fas and FasL are Epo-responsive homeostatic
regulators of erythropoiesis, a function independent of immune
cells or cytokines.
Materials and methods
Mice
Balb/C (Charles River Laboratories, Wilmington MA), lpr (B6.MRL-
Tnrfsf6lpr/j), gld (B6Smn.C3-Tnfsf6gld/j), and C57BL/6J mice (Jackson
Laboratories, Bar Harbor, ME) were between 6 and 12 weeks old.
Antibody staining and flow cytometry
Freshly isolated bone marrow or spleen was strained through a 40-m
strainer in the presence of phosphate-buffered saline and 5% fetal calf
serum (PBS/5% FCS). Cells were immunostained for 20 minutes at 4°C in
the presence of rabbit IgG (Jackson ImmunoResearch, West Grove, PA),
1 g/mL fluorochrome-conjugated anti-Ter119 (BD Biosciences, San
Diego, CA), and 1 g/mL fluorochrome-conjugated anti-CD71 (BD
Biosciences). 7-AAD (BD Biosciences) or DAPI (Roche, Indianapolis, IN)
was used to exclude dead cells. Staining for Fas or FasL was for 1 hour with
5 g/mL biotin-conjugated anti-Fas (Jo2 clone,52 BD Biosciences) or 5
g/mL biotin-conjugated anti-FasL (MFL3 clone,53 BD Biosciences) and
APC-conjugated streptavidin. To stain for Fas and FasL simultaneously, a
FITC–anti-Fas antibody was amplified with a secondary anti-FITC anti-
body. Annexin V staining was carried out according to the manufacturer’s
instructions (BD Biosciences). Activated caspase 3 was measured in cells
that were first surface labeled for Ter119 and CD71, then fixed, permeabil-
ized, and labeled with a polyclonal rabbit anti–activated caspase 3 (BD
Biosciences) or isotype control. In each experimental protocol, the same
antibody specificities were used with at least 2 different fluorochrome
combinations, yielding similar results. Control samples included unstained
cells, single-color controls, and “fluorescence minus one” controls, in each
of which one color in turn was missing, to establish the true background for
each channel following compensation. Cells were analyzed on a FACSCali-
bur or LSRII (BD Biosciences) flow cytometers. Data were analyzed with
FlowJo software (Tree Star, Stanford University, Stanford, CA). Cell
sorting was on a DakoCytomation MoFlo (Fort Collins, CO).
Quantitative real-time PCR
RNA was prepared from freshly sorted erythroblasts (Ery.A; see “Identifica-
tion of stress-responsive erythroblast subsets in adult mouse tissue using
flow cytometry”) using the RNeasy kit (Qiagen, Valencia, CA), treated with
DNaseI (Invitrogen, Carlsbad, CA) and concentrated with RNeasy MinElute
Cleanup kit (Qiagen). Reverse-transcription was performed using 1 g
RNA/sample, using superscript II (Invitrogen) and random hexamer
primers. Real-time polymerase chain reaction (PCR) was conducted on an
Applied Biosystems (San Diego, CA) 7300 real-time PCR system. TaqMan
probes were used for 18S ribosomal RNA (Applied Biosystems catalogue
no. 4308329), Fas (catalogue no. Mm00433237), and FasL (catalogue no.
Mm00438864). SYBR-green real-time PCR in conjunction with the
following primers were used for -actin (CACCGAGGCCCCCCT and
TTGAAGGTCTCAAACATGATCTGG) and for FasB (GAGGCCCATTT-
TGCTGTCAA and CCTACGTGGCCAGGAATCAG). A single PCR prod-
uct for each of these PCRs was confirmed by gel electrophoresis and by
melting-curve analysis. In all cases, no product was obtained in the absence
of template or the absence of reverse transcriptase.
Results
Identification of stress-responsive erythroblast subsets in
adult mouse tissue using flow cytometry
We previously developed a flow cytometric assay to identify
stage-specific erythroblasts directly in hematopoietic tissue.17 We
and others have applied this assay in the study of erythroblasts in
vivo.17,54-59 Intermediate levels of Ter119 (Ter119medCD71high)
identify proerythroblasts (ProEs).17 Ter119high cells are subdivided,
based on their expression of the transferrin receptor (CD71), which
declines with erythroblast maturation. However, the decline in
CD71 appeared gradual, without the formation of well-resolved
subpopulations. This resulted in the need to subdivide Ter119high
erythroblasts arbitrarily into high, medium, and low expressors of
CD71, corresponding to increasingly mature erythroblasts.17
In the present work we distinguished well-resolved erythroblast
subpopulations by considering, in addition to Ter119 and CD71, the
forward scatter (FSC) parameter. FSC is a function of cell size and
had been used previously to assess erythroblast maturation, indepen-
dently of cell-surface marker expression.17,60 Figure 1A shows that
when Ter119high cells are analyzed using both the CD71 and FSC
parameters, they consistently resolve into 3 principal populations,
which we labeled A, B, and C erythroblasts (Ery.A, Ery.B, and
Ery.C). Cytospin analysis of these subpopulations shows that they
form a developmental sequence. Ery.A (Ter119highCD71highFSChigh)
are basophilic, Ery.B (Ter119highCD71highFSClow) are late baso-
philic and polychromatic, whereas Ery.C (Ter119highCD71lowFSClow)
are orthochromatic erythroblasts and reticulocytes (Figure 1B).
We found that the ProE, Ery.A, Ery.B, and Ery.C subsets differ
in their sensitivity to stress. We mimicked the effect of acute stress
by injecting mice with a single dose of Epo (50 mg/kg). Figure 2
shows ensuing changes in hematopoietic tissue in vivo. Spleen size
increased approximately 2.5-fold by 72 hours after injection
(Figure 2A) and there was an associated increase in hematocrit
(Figure 2B). The frequency of Ter119 cells within the spleen
increased to 1.6-fold the basal level by 72 hours (Figure 2C).
Therefore, the absolute number of all splenic Ter119 cells
increased 2.5 1.6 4-fold at this time. The frequency of Ter119
cells also increased in bone marrow (Figure 2C).
We found that the relative proportions of the various erythro-
blast subsets altered following Epo injection. By 72 hours, the
proportion of splenic ProEs and Ery.A within Ter119 cells
increased 10-fold and 6-fold, respectively, their absolute number
increasing 40-fold and 24-fold (Figure 2D-F). In bone marrow,
where the basal levels of ProEs and Ery.A are higher than in spleen,
their proportion also increased, peaking by 24 hours (Figure 2D-F).
There was an approximately 2-fold, delayed increase in the
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proportion of splenic and bone marrow Ery.B, their absolute
number increasing approximately 8-fold by 96 hours. The propor-
tion of the most mature, Ery.C subset, declined 4-fold in spleen,
suggesting their absolute number remained unchanged.
The rapid increase in ProEs and Ery.A suggests they are a direct
Epo target during stress. The delayed response of Ery.B suggests
they are less responsive to Epo. Their increase may be secondary to
that in Ery.A, from which they arise. The lack of a significant
increase in Ery.C by 96 hours may reflect the time required for their
maturation from earlier precursors and may be contributed to by the
accelerated release of late erythroblasts from hematopoietic tissue
in response to high Epo.
The frequency and survival of ProEs and Ery.A in spleen is
lower than in bone marrow
In the basal state, Ery.A and ProEs were present at lower
frequencies in spleen than in bone marrow (Figures 2F and 3A), in
inbred mouse strains Balb/C and C57BL6, and in mixed genetic
background mice (C57BL6  129). In Balb/C (n  7), the mean
frequency of ProEs within Ter119 cells was 2.5% 0.5% (mean
SEM) in bone marrow but only 0.5%  0.1% in spleen (P  .01,
2-tailed Student t test).The frequency of Ery.Ain spleen was 11% 3.2%
compared with 26% 3.4% in bone marrow (P .01).
We examined the survival of early erythroblasts in bone marrow
and spleen using annexin V binding61 and caspase 3 activation.62
Freshly isolated spleen and bone marrow cells were labeled for
expression of CD71 and Ter119, annexin V binding, and the
viability dye 7-amino-actinomycin D (7-AAD),63 and examined by
flow cytometry. Figure 3B shows a representative analysis of
annexin V binding in Ery.A. Figure 3C summarizes results from
several similar experiments for each of the erythroblast subsets.
Annexin V binding was 3-fold higher in Ery.A in spleen than in
bone marrow (P  .001). Significantly higher annexin V binding
was also seen in splenic ProEs and Ery.B compared with the
equivalent bone marrow subsets.
Figure 2. Epo-responsive erythroblast subsets in bone marrow and spleen. Wild-type mice were injected with a single dose of Epo (50 mg/kg) or an equal volume of saline, and followed
for up to 96 hours. Bone marrow and spleen cells were freshly isolated and analyzed.The results of 7 independent experiments were pooled. Each data point is the meanSEM of 2 to 9 mice.
Each experiment contained mice of a single sex or an equal number of females and males. There was no significant difference between the Epo response of male and female mice. (A-C) Epo
caused a transient increase in spleen weight (A), hematocrit (B), and in the proportion of Ter119 cells in both bone marrow (Ci) and spleen (Cii). (D-E) Examples of flow cytometric histograms
of bone marrow (D) and spleen (E) cells labeled with Ter119 and CD71 antibodies and analyzed as illustrated in Figure 1. There is a clear increase in the proportions of the ProE and Ery.A
subsets in both tissues, with a moderate increase in Ery.B. (F) Changes in the relative frequencies of erythroblast subsets within the Ter119 compartment in bone marrow or spleen, following
Epo injection or a control saline injection. Data were analyzed as illustrated in panels D-E, and mean values for data pooled from 7 experiments are presented.
Figure 1. Definition of flow cytometric erythroblast subsets. (A) Flow cytometric
analysis of freshly isolated bone marrow cells labeled with antibodies against Ter119
and CD71. Dead cells were excluded with 7-AAD. The left panel shows all viable
bone marrow cells. Ter119high cells are further analyzed with respect to their forward
scatter (FSC) in the right panel. (B) Cytospin preparations of cells sorted from the
ProEs and Ery.A, B, and C subsets shown in panel A are stained for hemoglobin with
diaminobenzidine and counterstained with Giemsa. Scale bar represents 5 m.
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To assess caspase 3 activation, splenic and bone marrow cells
were labeled for cell-surface Ter119 and CD71, and intracellularly
for the activated form of caspase 3. In spleen, a higher proportion of
Ery.A was positive for activated caspase 3, compared with bone
marrow Ery.A (Figure 3D). Thus, by 2 independent measures of
apoptosis, splenic Ery.A undergo significantly more apoptosis than
equivalent bone marrow cells.
Fas and FasL are coexpressed by splenic early erythroblasts
The higher apoptosis of splenic early erythroblasts (Figure 3B-D)
may account for their lower relative frequencies (Figure 3A). We
therefore examined potential apoptotic regulators of early erythro-
blasts. Fas and FasL have been detected on cultured erythro-
blasts.34-36 To examine their expression in vivo, we labeled freshly
explanted splenic and bone marrow cells for cell-surface Ter119,
CD71, and either Fas or FasL. We found that erythroblasts
expressed both Fas and FasL (Figure 4A-B). The highest expres-
sion frequencies for both Fas and FasL were in the least mature,
ProE and Ery.A subsets, and declined with erythroblast maturation.
Only a proportion of ProE and Ery.A subsets, however, expressed
Fas or FasL. Of note, Fas and FasL were expressed by a
significantly higher proportion of splenic, compared with bone
marrow, erythroblasts. There was no significant difference between
bone marrow and spleen, however, in Fas and FasL expression by
nonerythroid cells (Figure 4A-B). Similar Fas and FasL expression
patterns were found in C57BL6/129 mice (Figure 4A-B) and in
Balb/C mice (not shown), with 30% to 50% of splenic Ery.A
expressing Fas and 60% to 80% expressing FasL.
Our finding that Fas and FasL are coexpressed in vivo within the
same erythroblast subsets differs from that reported for cultured
human erythroblasts,35,64 where Fas and FasL appeared to be
expressed sequentially in differentiation. To investigate this further,
we sorted freshly isolated ProEs or Ery.A expressing either Fas or
FasL and compared their morphology in cytospin preparations (not
shown). We found that, within a given erythroblast subset, cells
expressing Fas had a similar morphology to cells expressing FasL,
confirming that even within a given subset, cells expressing Fas or
FasL are of a similar maturation.
We examined whether Fas and FasL are coexpressed within the
same cell by labeling spleen and bone marrow cells simultaneously
with antibodies directed against Fas and FasL, as well as Ter119
and CD71. We found that, within splenic Ery.A, more than 90% of
cells expressing Fas also coexpress FasL (Figure 4C).
Fas-positive erythroblasts in vivo are more likely to bind
annexin V
The tissue and differentiation stage pattern of erythroblast Fas and
FasL expression (Figure 4A-B) was similar to that of annexin V
binding (Figure 3C). We therefore examined whether Fas may be
responsible for splenic erythroblast apoptosis. We asked whether,
within the same erythroblast subset, Fas-positive cells are more
likely to express annexin V than Fas-negative cells. We labeled
freshly isolated spleen and bone marrow cells simultaneously with
annexin V and with antibodies against Fas, Ter119, and CD71.
Fas-positive ProEs (not shown) and Ery.A (Figure 4D) bound
annexin V with higher frequencies than Fas-negative cells of the
Figure 3. Lower frequency and higher apoptosis of splenic early erythroblast subsets in the basal state. (A) The ProE and Ery.A subsets are a lower proportion of
Ter119 cells in spleen than in bone marrow. Data are the mean  SEM from Balb/C mice (n  7). *Student t test (2-tailed, unequal variance), P  .01. (B) Higher annexin V
binding of splenic Ery.A compared with equivalent bone marrow cells. Viable cells (impermeable to 7-AAD) from either bone marrow (top panels) or spleen (bottom panels)
were analyzed for Ter119/CD71 expression. Ter119high cells were gated and further analyzed with respect to FSC. FSChighCD71high cells (Ery.A) were examined for annexin V
binding (right panel). Background fluorescence in the annexin V channel was determined by comparison with Ery.A cells stained for all colors except for annexin V
(“fluorescence minus one” or FMO-annexin V, gray curve). The following fluorescent conjugates were used: CD71-FITC, Ter119-APC, 7-AAD, annexin V–Alexa Fluor 350.
Controls included unstained cells, single-color controls, and FMO controls. (C) Higher annexin V binding in splenic erythroblasts compared with equivalent bone marrow
erythroblasts. Staining strategy and data analysis as in panel B, for each of the indicated erythroblast subsets. Mean SEM, Balb/C mice (n  4); *P  .003; **P  .001. (D)
Higher proportion of cells positive for activated caspase 3 in splenic than in bone marrow Ery.A. The proportion (%) of cells staining positive for caspase 3 in each tissue is
indicated. Representative experiment; tissue from 2 Balb/C mice.
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same subset. Thus, 90% of Fas-positive splenic Ery.A bound
annexin V compared with only 40% of Fas-negative splenic Ery.A.
Similarly, more than 60% of bone marrow Fas-positive Ery.A
bound annexin V, compared with only 10% of equivalent Fas-
negative cells (Figure 4D). Further, the level of Fas expression
directly correlated with annexin V-binding, and virtually all cells
expressing the highest levels of Fas were positive for annexin V
(Figure 4E). For a given Fas expression level, bone marrow Ery.A
were consistently less likely to be annexin V positive than splenic
Ery.A (the red curves are right-shifted relative to the blue curves;
Figure 4E). Because Fas-mediated apoptosis requires the Fas-FasL
interaction, this difference may be due to the lower frequency of FasL
expression in bone marrow Ery.A (Figure 4B). The presence of splenic
Ery.A that are Fas negative but annexin V positive suggests that, in
addition to Fas, other apoptotic regulators are active in these cells.
The strong correlation, at the single-cell level, between Fas
expression and annexin V binding suggests that Fas expressed by
early erythroblasts in vivo is functional and is mediating cell death
in the basal state.
Fas expressed by freshly isolated Ery.A and Ery.B is functional
Erythroblasts differentiating in vitro express functional Fas.34-36 To
confirm that Fas expressed by freshly isolated erythroblasts is also
functional, we incubated freshly sorted splenic Ery.A or Ery.B for
up to 6 hours in the presence of Epo (0.05 U/mL) and either in the
presence or absence of the agonistic anti–mouse Fas antibody
Jo2.52 Apoptosis was assessed using annexin V-binding and found
to be higher in Ery.A than in Ery.B (Figure S1, available on the
Blood website; see the Supplemental Figures link at the top of the
online article). The presence of the agonistic anti-Fas antibody
significantly increased annexin V binding in both subsets, suggest-
ing splenic erythroblasts express functional Fas.
Analysis of lpr and gld mice
We examined mice mutant for Fas (lpr) or its ligand (gld).50 Splenic
ProE. and Ery.A in lpr and gld mice were present at higher
frequencies than in matched, wild-type mice (Figure S2). These
findings are consistent with Fas-mediated apoptosis of ProE. and
Ery.A in wild-type mice in the basal state (Figure 4). However, a
proportion of lpr and gld mice suffered mild to moderate anemia, a
consequence of their autoimmune syndrome.50 Therefore, in-
creased ProE. and Ery.A frequency may reflect, in part, a stress
response to anemia. We are currently developing mouse models
that would enable us to distinguish these possibilities.
Fas and FasL expression in mouse models of chronic
erythropoietic stress
Fas-mediated apoptosis of splenic early erythroblasts would limit
basal erythropoietic rate. We therefore asked whether, during
stress, erythroblasts become resistant to Fas-mediated apoptosis.
Mice heterozygous for b1 and b2 adult globin gene deletions
suffer -thalassemia (-thal), manifesting low hematocrits
(34%  1.7%, mean SD, n  7, compared with 45%  2.5% in
wild-type littermates, n  12), compensatory splenomegaly, and
erythroid hyperplasia.65 We examined freshly isolated spleen and
bone marrow from adult -thal mice and from wild-type litter-
mates. We found a clear increase in the number of Ter119 cells in
Figure 4. Fas and FasL are coexpressed by early erythroblasts and mediate early erythroblast apoptosis in vivo. (A-B) Expression of Fas (A) or FasL (B) in spleen and
bone marrow cells. Both Fas and FasL are expressed at higher frequencies in ProE and Ery.A subsets. Both are also expressed at higher frequencies in spleen than in bone marrow.
Freshly isolated spleen and bone marrow were labeled with antibodies against Ter119, CD71, and either Fas (Jo2) or FasL (MFL3). Staining strategy and analysis were similar to those
described in Figure 3. Data from C57BL6/129 mice, n 5, mean SEM. *P .004; **P .001. (C) Fas and FasL are coexpressed by Ery.A in spleen (top left panel) and bone marrow
(top right panel). Ter119/CD71/FSC analysis was used to gate Ery.A, as illustrated in Figure 1. Bottom panels show FMO controls (Figure 3B), which were used to set background
fluorescence in Ery.A. These lack either Fas or FasL primary antibodies, as indicated, but contain secondary and all other primary antibodies. Representative of 3 experiments. Two
different combinations of fluorescent conjugates gave similar results. (D-E) Single-cell analysis of Fas expression and annexin V binding in spleen and bone marrow Ery.A. Freshly isolated
bone marrow and spleen cells were simultaneously labeled with annexin V and with antibodies to Ter119, CD71, and Fas. Fas-positive Ery.Aare several-fold more likely to bind annexin V
than Fas-negative cells (D). In panel E, Ery.A were subdivided into 8 subsets of increasing Fas expression, measured as geometric mean fluorescence per cells. Fas expression is
correlated with annexin V binding, in both spleen and bone marrow. Data are from Balb/C mice (n 2).
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spleen, from 43%  1.7% (mean  SEM, n  8) to 68%  2.7%
(n  8, P  .001), reflecting erythroid hyperplasia. The frequen-
cies of Ery.A and Ery.B increased disproportionately, 10-fold and
5-fold, respectively (Figure 5A,C upper panels). There were also
significant increases in the frequencies of bone marrow early
erythroblasts (Figure 5D upper panel).
Early erythroblast expansion was associated with a significant
reduction in cell-surface Fas/FasL in -thal mice compared with
wild-type littermates (Figure 5B-D). There was a 3-fold reduction
in Fas-positive splenic Ery.A. The frequency of FasL-positive cells
in -thal mice fell 2-fold and 3-fold in splenic Ery.A and Ery.B,
respectively (P  .001). Cell-surface Fas and FasL in wild-type
bone marrow Ery.A is already low, but it declined further in -thal
mice (Figure 5D). Unlike erythroblast Fas/FasL, there was no
down-regulation of Fas or FasL in nonerythroid cells in -thal
spleen or bone marrow (Figure 5C-D).
We also examined mice with a kidney- and liver-specific
deletion of the von Hippel-Lindau (VHL) gene (ts-VHL	/	
mice).66,67 The constitutively elevated Epo in these mice68 leads to
chronic erythrocytosis,66 with hematocrits ranging from 65% to
80% compared with 45% to 55% in wild-type littermates.66 They
manifest moderately enlarged spleens with increased numbers of
Ter119 cells. The frequency of splenic Ery.A and Ery.B is
increased (Table 1). This is associated with a 4-fold and 2-fold
decrease in the frequency of Fas-positive splenic ProEs and Ery.A,
respectively. FasL expression was also significantly lower (Table 1).
There were no significant changes in erythroblast frequencies or
Fas/FasL expression in ts-VHL	/	 bone marrow.
Pregnancy is a subacute form of erythropoietic stress.69 We
examined freshly isolated bone marrow and spleen from pregnant
Balb/C mice and compared them with strain and age-matched
nonpregnant females. We found a 10% increase in the frequency of
Ery.A in both spleen and bone marrow, relative to all Ter119 cells
(P  .05, n  5). This was associated with a statistically significant
decrease in cell-surface Fas and FasL expression in Ery.A in both
spleen and bone marrow (Table 2).
Taken together, early erythroblast cell-surface Fas and FasL are
down-regulated in erythropoietic stress conditions of different
etiologies: -thalassemia, ts-VHL	/	 mice, and pregnant mice.
This suggests that down-regulation of Fas and FasL expression
may be intrinsic to the erythropoietic stress response itself.
Acute Epo administration leads to down-regulation of
erythroblast Fas and FasL
Erythropoietic stress is regulated by several hormones and cyto-
kines.70-73 To examine the role of Epo in Fas/FasL down-regulation
during stress, we injected wild-type Balb/C mice with a single Epo
dose (50 mg/kg subcutaneously), or with an equal volume of saline
(Figures 2 and 6), and examined changes in erythroblast frequen-
cies (Figure 2), apoptotic markers and Fas/FasL expression (Figure
6) over the ensuing 96 hours. Epo caused a fall in cell-surface Fas
and FasL, which reached their lowest levels in splenic Ery.A by
48 hours, beginning to recover toward baseline levels by 96 hours
(Figure 6A-B). In parallel, there was a fall in annexin V binding in
ProEs and Ery.A (Figure 6A,C), and a decline in activated caspase
3 (Figure 6D). These data suggest that high Epo, alone, is sufficient
to cause down-regulation of cell-surface Fas and FasL in splenic
early erythroblasts.
Quantitative real-time PCR of Fas, FasB, and FasL mRNA
To examine the mechanisms of Fas/FasL down-regulation during
stress, we measured early erythroblast Fas and FasL mRNA as well
as mRNA for the alternatively spliced, soluble FasB isoform, using
quantitative real-time PCR. RNA was prepared from freshly sorted
splenic Ery.A, from mouse models of stress, or from matched
control mice (Figure 6E; Table 3). Total Fas mRNA decreased
significantly by 24 hours following Epo injection and was 5-fold
lower than the basal level by 72 hours (Figure 6E). mRNA levels
for FasL also decreased. FasB mRNA decreased in parallel with
total Fas mRNA (Figure 6E). These results are consistent with
Epo-mediated suppression of Fas and FasL transcription. Alterna-
tively, Epo may mediate increased degradation of Fas or FasL mRNA.
We also examined Fas, FasB, and FasL mRNAs in splenic
Ery.A from -thal and ts-VHL	/	 mice and compared them with
matched controls (Table 3). In both these mouse models, there was
Figure 5. Down-regulation of cell-surface Fas and FasL in early erythroblasts
from -thal mice. (A) Representative flow cytometric histograms showing an
example of the changes found in erythroblast frequencies within Ter119 cells in
spleen in a -thal mouse compared with a littermate wild-type mouse. (B) Represen-
tative flow cytometric histograms of Fas and FasL expression in spleen Ery.A, B, and
C, in -thal erythroblasts, and in erythroblasts from a wild-type littermate. The
percentage of Ery.A positive for Fas relative to FMO control (not shown) is shown in
red. The percentage of Ery.B positive for Fas is shown in blue. (C-D) Changes in
erythroblast subset frequencies, and in Fas and FasL expression, in spleen (C) and
bone marrow (D), in -thal mice (n  8) compared with littermate wild-type mice
(n  8). Data are mean  SEM. Spleen and bone marrow cells were analyzed as
illustrated in panels A-B. *P  .05, **P  .01, ***P  .001, ****P  .001.
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a significant decrease in Fas and FasB mRNA. Fas mRNA was
6-fold lower in -thal mice than in wild-type littermates and 3-fold
lower in ts-VHL	/	 mice. These mRNA levels correlate well with
the more pronounced fall in splenic Ery.A surface Fas expression in
-thal than in ts-VHL	/	 mice (Figure 5; Table 1). FasL mRNA
was significantly reduced in ts-VHL	/	 mice, suggesting, in
agreement with our results in mice injected with Epo, that Epo
suppresses FasL mRNA expression. However, in -thal mice,
where the stress response is likely to be mediated by Epo in
cooperation with other stress factors, the levels of FasL mRNA
were more variable (Table 3).
The frequency of splenic Ery.A is a function of their
Fas expression
We asked how Fas expression in Ery.A correlates with Ery.A
expansion (Figure 7A), across all the erythropoietic models we
examined. We plotted the mean increase in Ery.A frequency for
each of the stress conditions against the corresponding mean
decrease in Fas-positive Ery.A. The increase in Ery.A frequency
was inversely related to the square of the fraction of Ery.A
expressing Fas. It is therefore likely that the decrease in Fas is itself
a function of the degree of erythropoietic stress. The fraction of
Ery.A that is Fas positive is, in turn, an important regulator of
Ery.A frequency.
Discussion
We defined stress-responsive erythroblast subsets in mouse hemato-
poietic tissue using flow cytometry. ProEs (Ter119medCD71high) and
Ery.A (Ter119highCD71highFSChigh) are morphologically equivalent
to proerythroblasts and basophilic erythroblasts, respectively, rep-
resenting consecutive, early stages in erythroblast terminal differen-
tiation (Figure 1). Proerythroblasts and basophilic erythroblasts
express the EpoR,28-30 consistent with the stress responsiveness of
ProEs and Ery.A. In response to a single Epo administration, the
absolute number of ProEs and Ery.A increased 20- to 30-fold, their
relative proportion within erythroid tissue increasing 5- to 10-fold
(Figure 2). We investigated the role of Fas-mediated apoptosis in
regulating the homeostasis of these cells. We found that ProEs and
Ery.A coexpress Fas and FasL. Based on measurements of their cell
frequency, cell survival, and Fas/FasL expression in the basal state
and in mouse models of erythropoietic stress, we propose that Fas
is a homeostatic regulator of erythropoiesis. Interactions between
splenic early erythroblasts coexpressing Fas and FasL lead to their
apoptosis, exerting a negative autoregulatory effect that limits basal
erythropoietic rate. With the induction of stress, high Epo sup-
presses expression of erythroblast Fas and FasL, resulting in
enhanced erythroblast survival and a consequent increase in
erythropoietic rate.
Fas mediates apoptosis of splenic early erythroblasts in the
basal state in vivo
In the basal state, ProEs and Ery.A were present at lower relative
frequencies, and were undergoing higher apoptosis, in spleen than
in bone marrow (Figure 3). Splenic ProEs and Ery.A expressed
significantly higher levels of Fas and FasL. Single-cell analysis
using multiparameter flow cytometry showed that 90% of Fas-
positive splenic Ery.A coexpressed FasL (Figure 4C). Further,
Fas-positive Ery.A were more likely to bind annexin V than
otherwise equivalent, Fas-negative Ery.A (Figure 4D-E). Fas
expressed by freshly isolated splenic erythroblasts is functional
(Figure S1). Taken together, these data suggest that interaction
Table 1. Down-regulation of splenic erythroblast cell-surface Fas/FasL in ts-VHL/ mice
Subset frequency, % of Ter119 cells Fas-positive cells, % FasL-positive cells, %
Control*;
n 6
ts-VHL/;
n 5 P †
Control*;
n 6
ts-VHL/;
n 5 P †
Control*;
n 6
ts-VHL/;
n 5 P †
Spleen
ProE 0.6  0.2 1.5  0.3 — 38  9 9  3 .023 66  4 36  9 .025
Ery.A 24  5 36  3 .044 48  6 26  3 .011 79  2 60  5 .018
Ery.B 24  4 39  3 .012 12  1 3  0.4  .001 37  4 12  4 .002
Ery.C 52  8 24  4 .045 0.6  0.1 0.3  0.1 — 1  0.2 0.6  0.2 —
Non-Ery NA NA — 47  4 47  6 — 10  0.2 9  1 —
Bone marrow
ProE 1.9  0.3 2.0  0.4 — 21  3 13  3 — 35  4 28  5 —
Ery.A 35  4 35  5 — 21  2 17  4 — 51  3 41  4 —
Ery.B 34  2 25  1 .001 2  0.5 1  0.2 — 9  2 6  2 —
Ery.C 29  4 38  6 — 0.3  0.05 0.3  0.1 — 0.6  0.1 0.3  0.1 —
Non-Ery NA NA — 51  4 50  3 — 15  4 18  5 —
Non-Ery indicates nonerythroid; NA, not applicable; and —, not significant.
*Matched littermates, number of mice indicated (n).
†Two-tailed Student t test, unequal variance, only for statistically significant differences at P  .05.
Table 2. Down-regulation of erythroblast Fas/FasL in pregnant mice
Fas-positive cells, % FasL-positive cells, %
Control*;
n 5
Pregnancy;
n 5 P †
Control*;
n 5
Pregnancy;
n 5 P †
Spleen
ProE 35  8 16  5 — 55  6 40  4 —
Ery.A 36  3 25  3 .022 73  5 59  3 .042
Ery.B 4  1 1.5  0.2 — 17  5 9  2 —
Ery.C 0.6  0.2 0.4  0.1 — 2  1.5 0.8  0.4 —
Non-Ery 30  4 33  5 — 5  0.6 5  1 —
Bone
marrow
ProE 18  4 12  4 — 43  10 16  4 —
Ery.A 13  1 9  1 .044 59  8 28  3 .013
Ery.B 0.7  0.1 0.7  0.1 — 7  2 4  2 —
Ery.C 0.3  0.1 0.4  0.1 — 1  0.5 0.6  0.4 —
Non-Ery 20  2 24  5 — 9  2 12  1 —
— indicates not significant.
*Age- and strain-matched (Balb/C) mice.
†Two-tailed Student t test, unequal variance, only for statistically significant
differences at P  .05.
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between splenic early erythroblasts coexpressing Fas and FasL
leads to their apoptosis, limiting splenic Ery.A and ProE frequency,
and consequently, erythropoietic rate.
Examination of lpr and gld mice is consistent with these
conclusions, showing higher frequencies of ProEs and Ery.A in
spleen compared with wild-type controls. Autoimmune anemia in
some of these mice raises the possibility that the increase in ProEs
and Ery.A may be due, in part, to a stress response. Recently, we
found that Fas and FasL are also coexpressed by a fraction of fetal
early erythroblasts, although at a lower level than in adult spleen.
Nevertheless, there was a significant increase in the number of
early erythroblast subsets in preimmune lpr and gld mice (manu-
script submitted).
The mechanism responsible for the higher expression of
Fas and FasL in splenic erythroblasts remains to be explained. It
is possible, as has been suggested recently,73 that there are
cell-autonomous differences between splenic and bone marrow
erythroid progenitors. Alternatively, differences between the
splenic and bone marrow microenvironments may differentially
regulate basal expression of erythroblast Fas and FasL.
Our finding that, in vivo, both Fas and FasL are coexpressed early in
terminal differentiation, contrasts with De Maria et al,35,64 who found
high Fas throughout terminal differentiation in cultured erythroblasts in
vitro, with FasL limited to late erythroblasts. In contrast, Krantz and
colleagues34 found both Fas and FasL expression in cultured human
erythroid colony-forming cells early in terminal differentiation, but
report only small numbers of cells expressing Fas ( 5%) and FasL
(13%). These lower levels may differ from those we find in vivo for
several reasons, including the bone marrow origin of the cells, possible
negative selection against cells expressing Fas in culture, or the high Epo
levels in the culture medium compared with that found in the basal state
in vivo.
High Epo suppresses Fas and FasL expression during stress
We examined -thal mice, ts-VHL	/	 mice, pregnant mice, and
mice injected with Epo. Across these distinct models of stress,
expansion in splenic early erythroblasts was associated with
significantly reduced cell-surface Fas and FasL (Figure 5; Tables
1-2). Further, there was an inverse correlation between Fas
Figure 6. Suppression of erythroblast Fas and FasL and decreased apoptosis following Epo injection. Wild-type Balb/C mice were injected with a single dose of Epo
(50 mg/kg) or with an equal volume of saline, and followed as described in Figure 2. Freshly isolated spleen cells were analyzed for Fas and FasL cell-surface expression and
mRNAs or for apoptotic markers. (A) Representative histograms of cell-surface Fas (left panels) and FasL (middle panels) expression or annexin V binding (right panels) in
Ery.A, B, and C, 48 hours following injection of either saline (top panels) or Epo (bottom panels). The percentage of Ery.A positive for Fas, FasL or annexin V is indicated in red,
and that of Ery.B in blue. (B) Time course of cell-surface Fas and FasL following Epo or saline injection. Results pooled from 5 experiments, normalized to initial Fas or FasL
levels; mean  SEM, n  2 to 7 mice per time point. (C) Time course of annexin V binding (geometric mean fluorescence) in ProEs (top panel) and in Ery.A (bottom panel)
following Epo administration. Results from duplicate mice are shown for each time point. (D) Changes in activated caspase 3 in splenic erythroblasts following Epo injection.
Splenic cells were labeled for Ter119 and CD71, were fixed and permeabilized, and then labeled with an antibody specific for activated caspase 3. Results from duplicate mice
are shown for each time point. (E) Time course of Fas, FasB, and FasL mRNA expression in splenic Ery.A following injection with Epo, measured using quantitative real-time
PCR, using RNA from freshly sorted splenic Ery.A. Bottom panels show the 

CT for the indicated mRNA between mice injected with Epo and those given saline injections,
normalized to actin mRNA. Each data point is the mean SEM of triplicate measurements in a single experiment using 1 to 2 Epo-injected mice and 1 to 2 saline-injected mice.
Two to 4 independent experiments were conducted per time point. Top panels show the mean fold change in mRNA at each time point, calculated as 2

CT, using the 

CT
values shown in the bottom panels. Each data point is the mean SEM for all the mice examined at each time point.
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down-regulation and Ery.A expansion across the various stress
models (Figure 7A). This suggests that the degree of Fas down-
regulation is a function of stress and serves as a principal
mechanism regulating splenic early erythroblast expansion.
Epo was sufficient to bring about down-regulation of erythro-
blast Fas/FasL (Figure 6). Following a single Epo administration,
Ery.A Fas/FasL reached their lowest level by 48 hours. This decline
was associated with enhanced Ery.A survival and their consequent
expansion. There was an approximately 24-hour delay in the
expansion of ProEs and Ery.A in spleen, compared with bone
marrow, following Epo injection (Figure 2). This delay may be due
to the higher initial Fas and FasL expression in splenic erythro-
blasts. There were no changes in Fas or FasL in nonerythroid cells
in any of the stress models, strongly suggesting that Epo is
mediating an erythroid-specific suppression of Fas and FasL.
Although the largest Fas and FasL changes were in splenic Ery.A,
smaller declines were also found in splenic Ery.B (Figures 5B-C;
Table 1) and in bone marrow erythroblasts (Figures 5D; Table 2),
cell types in which the baseline level of Fas and FasL is already
low. Therefore, Epo-mediated suppression of Fas and FasL expres-
sion is likely to be an integral part of EpoR stress signaling in all
EpoR-expressing erythroblasts.
Multiple mechanisms of Fas and FasL down-regulation from
the cell surface have been documented, including relocalization
within the cell, protease action, and transcriptional regulation.32
Here we found that mRNAs encoding Fas and FasL decline by 24
hours following Epo administration and are also significantly lower
in mouse models of chronic stress compared with matched
controls. These findings are consistent with EpoR-mediated suppres-
sion of Fas and FasL transcription. Alternatively, EpoR signaling
may increase Fas/FasL mRNA degradation.
A graded stress response may be a result of multiple
Epo-activated antiapoptotic pathways
The Stat5-bcl-xL antiapoptotic pathway in early erythroblasts is
required for normal hematocrit16-18 and for an efficient stress
response.17 Here we show that early erythroblast survival is also
regulated through Epo-mediated suppression of Fas/FasL during
stress. An increase in cell division does not appear to play a part in
the acute stress response of early erythroblasts26 (Y.L. and M.S.
unpublished observations, December 2004).
Figure 7. Frequency of splenic Ery.A is a function of their Fas expression. (A)
The frequency of splenic Ery.A is a function of their Fas expression. Each data point is
derived from the mean values of Ery.A frequency and Fas expression presented for
each erythropoietic stress model in Figures 5-6 and Tables 1-2. The same data are
presented with either linear axes (left panel) or logarithmic axes (right panel). Ery.A
frequency is expressed as a ratio of mean Ery.A frequency in the stressed mice to
mean Ery.A frequency in matched controls. The fraction of Fas-positive Ery.A is
calculated as the ratio of mean Fas-positive Ery.A in the stressed mice to the mean
Fas-positive cells in matched controls. The slope of the line in the left panel is (	1.9),
and the data fit the equation y  0.82x	1.9 (R2  0.912), where y is Ery.A frequency
and x is Ery.A Fas expression. If only chronic erythropoietic stress models are
considered (ie, pregnancy and Epo injection are omitted), the equation describing the
data becomes y  1.00x	1.9 (R2  0.9999). (B) The homeostatic role of Fas in
splenic early erythroblasts and in T cells. Splenic early erythroblasts coexpress Fas
and FasL in the basal state, resulting in continuous apoptosis. Erythropoietic stress
leads to Epo-mediated down-regulation of Fas and FasL expression and enhanced
erythroblast survival, increasing erythropoietic rate. In contrast, naive T cells do not
express Fas and FasL in the basal state. Fas/FasL expression is induced following
T-cell activation and clonal expansion, when Fas-mediated apoptosis is key in
activation-induced cell death.
Table 3. Quantitative real-time PCR for Fas, FasL, and FasB mRNAs in chronic erythropoietic stress
Mouse strain*
Fas FasL FasB
CT†
Fold decrease
in mRNA‡ CT†
Fold decrease
in mRNA‡ CT†
Fold decrease
in mRNA‡
ts-VHL/
Experiment 1 1.12  0.29 — 0.99  0.42 — 1.12  0.80 —
Experiment 2 2.61  0.09 — 2.52  0.17 — 2.64  0.86 —
Experiment 3 2.05  0.17 — 1.44  0.16 — 2.51  0.50 —
Experiment 4 1.00  0.13 — 1.19  0.07 — 0.49  0.30 —
Mean 1.70  0.38 3.2 1.54  0.34 2.9 1.69  0.52 3.2
-thal
Experiment 1 1.75  0.28 — 0.16  0.66 — 2.29  0.90 —
Experiment 2 3.56  0.26 — 1.9  0.24 — 4.3  0.09 —
Experiment 3 2.35  0.07 — (	0.5)  0.47 — 2.14  0.08 —
Mean 2.55  0.53 5.9 0.52  0.7 1.4 2.92  0.70 7.6
*RNA prepared and real-time PCR carried out independently for each experiment, from Ery.A sorted from at least one -thal or ts-VHL	/	 mouse and one matched
littermate.
†Mean  SD of 

CT from triplicate samples for each experiment. 

CT is the difference in cycle number for the indicated mRNAs, between template RNA from -thal or
ts-VHL	/	 mouse and its matched littermate, relative to -actin mRNA in each sample.
‡Calculated as 2 to the power of the mean 

CT for all experiments.
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It is not yet clear how, and to what extent, the dynamic range of
the erythropoietic stress response can be generated through antiapo-
ptotic signaling in early erythroblasts. It has been proposed that
increasingly higher Epo levels activate a graded antiapoptotic
signal, rescuing correspondingly larger fractions of early erythro-
blasts from apoptosis. Consistent with this model, proerythroblasts
exhibit a spectrum of sensitivities to apoptosis.74 The spectrum of
erythroblast Fas expression we document here suggests a
potential molecular mechanism for this varying sensitivity. The
mechanism giving rise to a graded antiapoptotic EpoR signaling
is not yet clear but may depend on the existence of multiple
antiapoptotic pathways. In addition to the Stat5-bcl-xL path-
way16-18 and the suppression of Fas, several other, Epo-
dependent antiapoptotic signals have been described in vitro,75-80
but their effect on erythroblast survival and erythropoietic rate
in vivo remains to be determined.
Our data suggest that, in the basal state, the erythropoietic
system continuously produces excess numbers of early erythro-
blasts, which become apoptotic through Fas-mediated signaling.
The principal advantage of a homeostatic mechanism that relies on
the production of excess cells is a reduction in the response lag time
during stress. A second advantage of a homeostatic mechanism that
relies on negative autoregulation of cell numbers is that it would
self-correct for small perturbations, maintaining a relatively con-
stant erythroblast population size in the basal state. Recently, using
computational modeling, we identified negative feedback of this
type, mediated through Fas and FasL, during the onset of erythroid
development in the fetal liver (manuscript submitted).
The regulation of erythroblast homeostasis by Fas and FasL
contrasts with their role in T-cell homeostasis (Figure 7B). Naive T
cells in the basal state do not express Fas or FasL but do so
following antigenic stimulation. In contrast, early erythroblasts in
the basal state do express Fas and FasL, but this expression is
down-regulated in response to stress. Other regenerating tissues
such as liver, skin, or intestinal epithelium, all of which express
Fas, may use a similar homeostatic mechanism to the one we
delineate in erythroblasts.
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